

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Clover Biopharmaceuticals, Ltd.**  
**三葉草生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2197)**

**POLL RESULTS OF THE ANNUAL GENERAL MEETING  
HELD ON JUNE 18, 2026**

**POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 18, 2026**

The board (the “**Board**”) of Directors (the “**Director(s)**”) of Clover Biopharmaceuticals, Ltd. (the “**Company**”) is pleased to announce the poll results of the annual general meeting of the Company (the “**Annual General Meeting**”) held at B5-19, Building 1, High-tech Incubation Park, No. 1480, Tianfu Avenue (North), Chengdu High-Tech Zone, China (Sichuan) Pilot Free Trade Zone on Thursday, June 18, 2026 at 10:00 a.m.

References are made to the Company’s circular (the “**Circular**”) in connection with the Annual General Meeting and notice of the Annual General Meeting (the “**Notice**”) dated May 27, 2026. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The poll results in respect of the resolutions proposed at the Annual General Meeting were as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended December 31, 2025.	474,110,105 (100.000000%)	0 (0.000000%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
2.	To re-elect the following persons:		
	(a) Mr. LIANG Joshua G, executive director	466,631,557 (98.422614%)	7,478,548 (1.577386%)
	(b) Dr. WANG Xiaodong, non-executive director	466,631,557 (98.422614%)	7,478,548 (1.577386%)
	(c) Mr. LIAO Xiang, independent non-executive director	474,110,105 (100.000000%)	0 (0.000000%)
3.	To authorise the board of directors of the Company to fix the remuneration of the directors.	466,631,557 (98.422614%)	7,478,548 (1.577386%)
4.	To re-appoint Rongcheng (Hong Kong) CPA Limited as the auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorise the board of directors of the Company to fix its remuneration.	474,021,605 (99.981333%)	88,500 (0.018667%)
5.	(A) To give a general mandate to the directors of the Company to allot, issue and deal with additional shares and/or sell or transfer treasury shares (if any) not exceeding 20% of the issued share capital of the Company (excluding treasury shares, if any) as at the date of this resolution.	466,543,057 (98.403947%)	7,567,048 (1.596053%)
	(B) To give a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the issued share capital of the Company (excluding treasury shares, if any) as at the date of this resolution.	474,097,105 (99.997258%)	13,000 (0.002742%)
	(C) To extend the authority given to the directors of the Company pursuant to ordinary resolution no. 5(A) to issue shares and/or sell or transfer treasury shares (if any) by adding to the issued share capital of the Company the number of shares repurchased under ordinary resolution no. 5(B).	466,543,057 (98.403947%)	7,567,048 (1.596053%)

Special Resolution		Number of Votes (%)	
		For	Against
6.	To approve the proposed amendments to the existing amended and restated memorandum and articles of association of the Company and to adopt the sixth amended and restated memorandum and articles of association of the Company (the “New M&A”) in substitution for, and to the exclusion of, the existing amended and restated memorandum and articles of association of the Company and to authorise any one director, the registered office provider or company secretary of the Company to do all things necessary to give effect to the proposed amendments and the adoption of the New M&A as set out in resolution No. 6 of the Notice.	474,110,105 (100.000000%)	0 (0.000000%)

Please refer to the Notice for the full text of the resolutions proposed at the Annual General Meeting.

As more than 50% the votes were cast in favour of each of the resolutions numbered 1 to 5 above, all such resolutions were duly passed as ordinary resolutions at the Annual General Meeting.

As not less than three-fourths of the votes were cast in favour of the resolution numbered 6 above, the said resolution was duly passed as a special resolution at the Annual General Meeting.

The total number of issued Shares as at the date of the Annual General Meeting was 1,298,413,056 Shares and the Company did not have any treasury shares. As set out in the Circular, the Trustee will abstain from voting on all resolutions to be proposed at the Annual General Meeting. Therefore, the Trustee, holding a total number of 54,288,147 Shares as at the date of the Annual General Meeting, has abstained from voting on all resolutions proposed at the Annual General Meeting.

Save as disclosed above, there were (i) no Shareholders being required under the Listing Rules to abstain from voting in respect of the resolutions at the Annual General Meeting and no Shareholders stating his/her/its intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the Annual General Meeting, (ii) no restrictions on any Shareholders casting votes on any of the proposed resolutions at the Annual General Meeting, and (iii) no Shares entitling the holders to attend and abstain from voting in favour of any resolution at the Annual General Meeting as set out in Rule 13.40 of the Listing Rules. Accordingly, the total number of shares of the Company entitling the holder to attend and vote on the resolutions numbered 1 to 6 above was 1,244,124,909 Shares as at the date of the Annual General Meeting.

Except for Dr. Xiaodong WANG, Dr. Donna Marie AMBROSINO, Dr. Xiaobin WU and Mr. Jeffrey FARROW who did not attend the Annual General Meeting due to business arrangements, all other Directors of the Company, namely Dr. Peng LIANG, Mr. Joshua G LIANG, Mr. Xiang LIAO and Mr. Thomas LEGGETT attended the Annual General Meeting, either in person or by means of electronic facilities.

Computershare Hong Kong Investor Services Limited, the branch share registrar in Hong Kong of the Company, acted as the scrutineer for counting of votes at the Annual General Meeting.

By order of the Board  
**Clover Biopharmaceuticals, Ltd.**  
**Dr. Peng LIANG**  
*Chairman of the Board*

Shanghai, PRC, June 18, 2026

*As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG and Dr. Donna Marie AMBROSINO as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.*